Moderna reports positive interim results from phase 1 CMV vaccine (mRNA-1647) study
Moderna announced positive data from the three-month interim analysis of safety and immunogenicity of the Phase 1 study of its investigational cytomegalovirus vaccine (mRNA-1647). mRNA-1647 is a wholly owned program in Moderna’s prophylactic vaccine portfolio. September 12, 2019